Understanding Acute Graft-Versus-Host Disease (aGvHD)

The Microbiota Connection

Recent research has highlighted the role of the host's microbiota in modulating GvHD. The organs most commonly affected by aGvHD—the skin, liver, and gastrointestinal tract—are all exposed to microbial pathogens via the epidermis, portal circulation, and intestinal mucosa. A high diversity of commensal microbiota is associated with protection against GvHD, likely through beneficial microbial metabolites like short-chain fatty acids and indoles, which support epithelial integrity and immunoregulation.

Clinical Manifestations and Diagnosis

aGvHD typically presents in three target organs. Diagnosis involves assessing the clinical signs and, in some cases, histopathological findings.

Target Organ Involvement

Staging and Grading

To standardize care, clinicians use a two-step system: Staging and Grading.

• Staging: This assesses the severity of involvement within each individual organ (e.g., Stage 1 skin, Stage 3 liver).
• Grading: This is a composite score based on the most severe organ involvement.

Exam Tip: Remember that the overall Clinical Grade is determined by the single most severe organ. For example, if a patient has Stage 1 skin involvement but Stage 3 liver involvement, the overall grade is Grade III.

Prevention and Prophylaxis Strategies

Because severe aGvHD has an extremely poor prognosis, prevention is a cornerstone of transplant medicine.

Pharmacological Prophylaxis

The most common approach is the use of immunosuppressive agents to limit donor T-cell function.

• Standard Combination: A calcineurin inhibitor (CNI)—either tacrolimus (TAC) or cyclosporine (CSA)—combined with methotrexate (MTX).
• Other Agents: Mycophenolate mofetil (MMF) and sirolimus (SIR) have also been utilized.
• Newer Approvals: Abatacept has been FDA-approved for prevention in matched or 1-allele mismatched unrelated donor transplants.

T-cell Depletion (TCD)

An alternative is to remove T cells from the graft before infusion. This can be done via:

• Ex vivo methods: Positive selection of $\text{CD34}^+$ stem cells.
• In vivo methods: Using polyclonal anti-thymocyte globulin (ATG).

While TCD is highly efficient at preventing GvHD, it carries a higher risk of infection and disease relapse. Consequently, it is often reserved for high-risk scenarios like haploidentical transplants.

Emerging Prophylaxis: PT-CY

Post-transplant cyclophosphamide (PT-CY) has shown significant promise, particularly in haploidentical transplantation. It works by eliminating early activated donor T cells. Studies have shown that PT-CY can significantly improve one-year graft-versus-GvHD relapse-free survival (GRFS) compared to standard CNI/MTX regimens.

Treatment of Advanced (Steroid-Refractory) aGvHD

For patients who do not respond to first-line treatment (typically high-dose methylprednisolone), the condition is termed steroid-refractory aGvHD (SR-aGvHD).

1. First-line: High-dose methylprednisolone (approx. $2\text{ mg/kg/day}$).
2. Second-line (Standard of Care): Ruxolitinib is the primary approved treatment for Grade 2–4 SR-aGvHD. Clinical trials demonstrated its superiority over investigator's choice in terms of overall response and complete response rates.
3. Other Investigational/Alternative Options:
   • Extracorporeal photopheresis: Often used with lower toxicity.
   • Mesenchymal Stromal Cells (MSCs): Show promise due to their non-HLA-restricted immunosuppressive effects.
   • Fecal Microbiota Transplantation (FMT): Specifically studied for steroid-resistant GI aGvHD.
   • $\alpha_1$-antitrypsin infusion: Aimed at stimulating regulatory T cells.

Clinical Note: Achieving a balance between suppressing the immune response to control GvHD and maintaining enough immunocompetence to fight viral and fungal infections is one of the greatest challenges in managing aGvHD.